New Antiretrovirals

873140 Exhibits Potent Antiviral Activity Against a Broad Panel of HIV-1 Envelopes From Treatment Naïve and Experienced Subjects. J. Demarest and others.

HIV Coinfection with HCV/HBV

Safety of Abacavir (ABC)+Lamivudine (3TC)-based HAART in ART-Naïve HIV-Infected Subjects With and Without Hepatitis B (HBV) and/or Hepatitis C (HCV) Co-Infection. H Zhao and others.

Long Term Safety in HCV/HBV Co-infected HIV ART Naïve Adults Treated with Fosamprenavir/ Ritonavir. E DeJesus and others.

Non Nucleoside Reverse Transcriptase Inhibitors (nNRTI)

Impact of Race on the Efficacy and Occurrence of Nervous System Symptoms (NSS) in HIV-Infected Subjects Following a Switch from a Protease Inhibitor (PI) to an Efavirenz (EFV)-Based Regimen. E DeJesus and others.

Nucleoside/tide Reverse Transcriptase Inhibitors (NRTIs)

Pharmacokinetic Effects of Coadministration of Atazanavir and Tenofovir at Steady State. S Agarawada and others.

Antiretroviral Activity and Tolerability of Reverset (D-d4FC), a New d4FC), a New Fluorocytidine Nucleoside Analog, When Used in Combination Therapy in Treatment-Experienced Patients: Results of Phase IIb Study RVT-203 C. Cohen and others.

Superior Outcome for Tenofovir DF, Emtricitabine and Efavirenz Compared to Fixed Dose Zidovudine/Lamivudine and EFV in Antiretroviral Naïve Patients. A Pozniak and others.

Protease Inhibitors (PIs) and Boosted PIs

Atazanavir Use in Pregnancy. A Morris and others.

Pharmacokinetic Effects of Coadministration of Atazanavir and Tenofovir at Steady State. S Agarawada and others.

Pharmacokinetic Interaction between Atazanavir and Omeprazole in Healthy Subjects. S Agarawada and others.


Efficacy of Atazanavir (ATV) Based HAART in Patients Switched From a Stable PI or Boosted PI (PI/r) Treatment. Planned Week 24 Analysis of a Phase IIIb 48-Week Multicenter, Open-label, Randomized, Prospective Study: The SWAN Study J. Gattell and others.

Immunologic Reconstitution Through 6 Years in Antiretroviral-Naïve Subjects Treated with Lopinavir/ritonavir (LPV/r) A. Landay and others.

Once-Daily vs.Twice-Daily Lopinavir/ritonavir in Antiretroviral-Naïve Patients: 96-Week Results J. Molina and others.

NRTI Sparing Trial (CTN 177): Antiviral and Metabolic Effects of Nevirapine (NVP) + Lopinavir/ritonavir (LPV/r) vs. Zidovudine/lamivudine (AZT/3TC) + NVP vs. AZT/3TC + LPV/r. M Harris and others.

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression. A randomized, controlled, open-label, pilot clinical trial. JR Arribas and others.

Significantly Reduced Food Effect and Pharmacokinetic Variability with a Novel Lopinavir/ritonavir Tablet Formulation. W Awni and others.

2-Year Follow-Up Lopinavir/ritonavir (LPV/r)- Efavirenz (EFV) Combination (BIKS Study) C Allavena and others.

Antiretroviral Treatment Intensification Leads to Accelerated CD4 Lymphocyte Recovery 4 Lymphocyte Recovery. K Smith and others.

Randomized Controlled Trial of Once Daily (QD) Tenofovir (TDF), 3TC and Lopinavir/ritonavir (LPV/r) versus Remaining on The Same Regimen in HIV-infected Patients Virologically Suppressed on Their First PI-containing HAART Regimen. M Loutfy and others.

Beneficial Effects of a Switch to a Lopinavir/rit (LPV/r)-Containing Regimen for Patients With Partial or No Immune Reconstitution With HAART Despite Complete Viral Suppression. D Pitrak and others.

Risk factors for loss of virological suppression at 48 weeks in patients receiving lopinavir/ritonavir monotherapy in the OK clinical trial. F Pulido and others.



Salvage Therapy" AND "Entry Inhibitors" Fuzeon (enfuvirtide)

An evaluation of HIV-patient QUAlity of LIfe (QoL) and Tolerability after administration of Enfuvirtide (ENF)-based HAART using a smaller needle in a community practice setting (QUALITÉ). A True, R DeMasi and R Falcon.